KDM3A regulates Slug expression to promote the invasion of MCF7 breast cancer cells in hypoxia

HYUN-JUNG AHN1, BYUL MOON1,2, MIJIN PARK1,2 and JUNG-AE KIM1,2

1Personalized Genomic Medicine Research Centre, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141; 2Department of Functional Genomics, Korea Research Institute of Bioscience and Biotechnology School of Bioscience, University of Science and Technology, Daejeon 34113, Republic of Korea

Received June 19, 2020; Accepted September 18, 2020

DOI: 10.3892/ol.2020.12199

Abstract. Oxygen deprivation (hypoxia), which frequently occurs in the tumour microenvironment, is a strong driver of the phenotypic transition of cancer cells. An increase in metastatic potential such as cell invasion is a well-known phenotypical change induced in hypoxia. The present study demonstrated that lysine demethylase 3A (KDM3A), a Jumonji C domain-containing KDM, is involved in the hypoxia-induced invasion of MCF7 breast cancer cells. KDM3A depletion inhibits the induction of cell invasion without affecting MCF7 cell survival rate or proliferation under hypoxic conditions, whereas KDM3A overexpression enhances MCF7 cell invasion even under normoxic conditions. KDM3A suppresses E-cadherin expression, which is associated with epithelial-to-mesenchymal transition (EMT)-mediated cell invasion in hypoxia. In addition, KDM3A promotes the expression of Slug, an EMT transcription factor that negatively regulates E-cadherin expression. Consistent with this finding, the removal of the repressive transcription marker, dimethylated histone H3 at lysine 9 from the Slug promoter is dependent on hypoxia-induced recruitment of KDM3A. Collectively, the results of the present study suggest that KDM3A is a crucial transcriptional coactivator of Slug expression to induce MCF7 breast cancer cell invasion in hypoxia, and that inhibition of KDM3A may efficaciously prevent metastatic cancer development.

Introduction

One of the most difficult challenges in developing anticancer treatment strategies is overcoming the phenotypic plasticity of cancer cells. Oxygen deprivation (also known as hypoxia) to a level lower than the physiological concentration is frequently accompanied by the rapid proliferation of cancer cells in vivo, and functions as a strong extracellular factor to stimulate cancer cell plasticity (1). In hypoxia, cancer cells induce various response pathways. To provide the energy necessary for cellular activities when the oxygen supply is scarce, cells upregulate anaerobic glycolysis-associated pathways (2). Angiogenesis is also stimulated to generate blood vessels for tumour growth (3). Furthermore, hypoxia enables the induction of the epithelial-to-mesenchymal transition (EMT) and subsequent cell motility, which reflect the phenotypical transition of cancer cells to aggressive metastasis (1).

The reprogramming of gene expression and/or signalling pathways is involved in hypoxia-induced changes in the state of cancer cells. Hypoxia-inducible factor-1 (HIF-1) is a key transcription factor involved in hypoxia-induced transcriptional alteration (4). Accumulation of HIF-1 in hypoxia alters the expression of numerous target genes, which mediates phenotypical changes in cancer cells. Chromatin alteration is also closely associated with hypoxia-induced transcriptional reprogramming. Among various chromatin modifications, histone lysine demethylation as a response to hypoxia is of particular interest, since Jumonji C (JmjC) domain-containing lysine demethylases (KDMs) require oxygen as a substrate for catalysis. While a lack of oxygen attenuates the activity of KDMs, the expression of multiple KDMs, some of which are HIF-1 dependent, is upregulated in hypoxic cells (5). Increased cellular levels of KDMs may compensate attenuated KDM catalytic activity. In addition, the direct molecular function of KDMs in hypoxia-induced responses have been reported: KDMs alter the chromatin structure of numerous target genes (6). These findings suggest that the mechanisms by which KDMs are involved in hypoxia-induced responses are important to understand the progression of aggressive forms of cancer.

Among the KDMs upregulated directly by HIF-1, KDM4C, which demethylates histone H3 at lysine 9 (H3K9), functions as a coactivator of HIF-1 and mediates breast cancer progression (7). KDM3A, another H3K9 demethylase, also enhances HIF-1 transcriptional activity. In endothelial cells, KDM3A associates with and demethylates H3K9 at the SLC2A3 locus in a HIF-dependent manner (8). KDM3A cooperates with HIF-1 to upregulate the expression of androgen receptor target genes in prostate cancer cells (9). KDM3A accumulation is
also required for the proliferation of different cancer cell lines under hypoxic conditions (10). Furthermore, gene expression profiling of mouse embryonic stem cells under hypoxia revealed that KDM3A knockout affected the expression of numerous hypoxia-responsive genes (11). These findings collectively suggest that KDM3A is an important chromatin regulator for hypoxia-induced transcriptional reprogramming to mediate aggressive cancer progression. Accordingly, to gain insight into developing a means to overcome cancer cell plasticity in hypoxic tumour microenvironments, the present study investigated the molecular mechanisms by which KDM3A functions in cancer cell phenotypic transitions in hypoxia.

Materials and methods

Cell culture. The MCF7 cell line was purchased from the American Type Culture Collection and was maintained in high-glucose Dulbecco’s modified Eagle’s medium (DMEM; Gibco; Thermo Fisher Scientific, Inc.) supplemented with 10% foetal bovine serum (Gibco; Thermo Fisher Scientific, Inc.) and 1X antibiotic-antimycotic (Gibco; Thermo Fisher Scientific, Inc.). To provide hypoxic culture conditions where oxygen levels were lower than physiological normoxic levels (21% O₂), cells were cultured in 1% (for cell death, invasion, reporter assay and ChIP assay) or 5% O₂ (for cell proliferation assay) with 5% CO₂ (MCO-5M; Sanyo Electric Co., Ltd.), while normoxic culture conditions were maintained under 21% O₂ with 5% CO₂ (Heraeus BB15 CO₂ Incubator; Thermo Fisher Scientific, Inc.).

Reagents, transfection and antibodies. Lipofectamine® Plus (Invitrogen; Thermo Fisher Scientific, Inc.) and RNAiMAX (Invitrogen; Thermo Fisher Scientific, Inc.) reagents were employed for DNA plasmid and small interfering (si)RNA transfection, respectively. siRNA against KDM3A (si-KDM3A; 5'-GUCUAUGUGGGAUAUCCCA-3') and a negative control (si-CTL; 5'-CCUACGCCACCAAUUUCGU-3') were purchased from Bioneer Corporation. The primary and secondary antibodies used in the present study were as follows: anti-KDM3A (Santa Cruz Biotechnology, Inc.; sc-376608; 1:1,000), anti-E-cadherin (Santa Cruz Biotechnology, Inc.; sc-271977; 1:1,000), anti-α-Snail (Santa Cruz Biotechnology, Inc.; sc-1666477; 1:1,000), anti-Flag (Sigma-Aldrich; Merck KGaA; F3165; 1:1,000), anti-β-actin (Santa Cruz Biotechnology, Inc.; sc-47778; 1:2,000), anti-Flag (Sigma-Aldrich; Merck KGaA; F3165; 1:1,000), anti-IgG chromatin immunoprecipitation (ChIP) grade (Abcam; ab2410; 1 µg/ml) and horseradish peroxidase-conjugated anti-rabbit IgG (EMD Millipore; AP132P; 1:5,000). A plasmid construct encoding Flag-KDM3A derived from pcDNA3.1 was provided by Dr Hyun-Soo Cho (Korea Research Institute of Bioscience and Biotechnology). SNAI2 promoter activity reporter constructs were co-transfected with luciferase reporter (0.05 µg) and si-CTL or KDM3A (100 nM). At 48 h post-transfection, the cells were exposed to hypoxic conditions for an additional 24 h. Luciferase activities were determined using a luminometer (Luminoskan Ascent; Thermo Fisher Scientific). To generate different 5' regions of reporter constructs with the shared 3' region, a common Rep-R primer was used for the subcloning of both Rep-A and Rep-B constructs.

Luciferase assay. Luciferase assay was performed using a Dual-Luciferase Reporter Assay System (Promega Corporation) according to the manufacturer’s instructions. Cells (7.5x10⁴/well) cultured in 12-well plates for 24 h were transfected with luciferase reporter (0.2 µg), Renilla reporter (0.05 µg) and si-CTL or KDM3A (100 nM). At 48 h post-transfection, the cells were exposed to hypoxic conditions for an additional 24 h. Luciferase activities were determined using a luminometer (Luminoskan Ascent; Thermo Fisher Scientific).
regions within the SNAI2 promoter and the downstream primer pairs used for the ChIP assays, which were specific to respectively measured by ImageJ (National Institutes of Health). The and extension at 72˚C for 15 sec, with a final extension at 72˚C denaturation at 94˚C for 20 sec, annealing at 55‑60˚C for 20 sec Pre‑denaturation at 94˚C for 5 min, followed by 20 cycles of DNA (1%) used for ChIP with individual antibody served as the control. The thermocycling conditions were as follows: 1.5%‑agarose gel stained with RedSafe™ (Intron, Inc.). Input samples were visualized by PCR and electrophoresed on a aldehyde at room temperature for 15 min. ChIP‑enriched DNA samples were used for ChIP with specific target proteins. The immunoblots were developed with LAS-4000 (Luminescent Image Analyzer; Fujifilm Wako Pure Chemical Corporation).

Invasion assays. The outsides of Transwell inserts were pre-coated with human collagen‑type IV at room temperature for 1 h. For the invasion assays, the upper chambers of the Transwell inserts were coated with 250 µg/ml Matrigel (Becton‑Dickinson and Company) at room temperature for 1 h. MCF7 cells were transfected with 0.1 µM si‑CTL or si‑KDM3A. At 24 h post-transfection, the cells were incubated under either hypoxic (1% O2) or normoxic (21% O2) conditions. After 24 h of incubation at different oxygen concentrations, the cells were harvested with 0.025% trypsin‑EDTA and stained with 0.5% crystal violet. The invaded cells were counted manually under a light microscope (x200 magnifications; 5 fields per replicate).

ChIP assay. ChIP assay was performed using a ChIP assay kit following the manufacturer's protocol (Upstate Biotechnology, Inc). Cells (2x10^6) were preincubated with a dimethyl 3,3'-dithio‑bispropionimidate‑HCl solution (5 mM; Pierce; Thermo Fisher Scientific, Inc.) for 30 min on ice and then treated with 1% formaldehyde at room temperature for 15 min. ChIP‑enriched DNA samples were visualized by PCR and electrophoresed on a 1.5%‑agarose gel stained with RedSafe™ (Intron, Inc.). Input DNA (1%) used for ChIP with individual antibody served as the control. The thermocycling conditions were as follows: Pre-denaturation at 94˚C for 5 min, followed by 20 cycles of denaturation at 94˚C for 20 sec, annealing at 55‑60˚C for 20 sec and extension at 72˚C for 15 sec, with a final extension at 72˚C for 5 min. Densitometry of visualized DNA was semi‑quantitatively measured by ImageJ (National Institutes of Health). The primer pairs used for the ChIP assays, which were specific to regions within the SNAI2 promoter and the downstream adjacent DNA element (from -1,500 to +1,000) separated by a ~200‑bp interval, as labelled in Fig. 4A, were as follows: A‑F, 5'‑ACCTGACATGATTTTCTTC‑3'; A‑R, 5'‑TCACTGAA GATCCACCTAATCTC‑3'; d‑F, 5'‑GGTTCTCTAAAATTTTA TCAAATCTA‑3'; d‑R, 5'‑AAGGCCATTAAATCCATC TCA‑3'; e‑F, 5'‑GTGAGAAATGTGCCGCTCTC‑3'; e‑R, 5'‑GGCTGTACGGAAGACTGGA‑3'; f‑F, 5'‑GGCAGGA GCCCTGTAGTAC‑3'; f‑R, 5'‑TGAAAAGGAAAGGGGG AAGGGGAGAG‑3'; B‑F, 5'‑CCCCCTTCCTGGCGGAC ACT‑3'; B‑R, 5'‑ACGCCTCTCGGGAGCTAG‑3'; g‑F, 5'‑CTG TTCACAGTGTCCCAAG‑3'; g‑R, 5'‑TTACGAACTG GCCCGTTTT‑3'; h‑F, 5'‑AGACCCCGCTGGCAGATG‑3'; h‑R, 5'‑TCTTCTTTCATTGTGTTGCTCA‑3'; i‑F, 5'‑TTCTGTT TGCTAAAGCGCTTG‑3'; i‑R, 5'‑GCCGCGTCTAAAGGA‑3'; C‑F, 5'‑AGCCCCATACGTAACATGGA‑3'; C‑R, 5'‑TGC ACGGAGCTATAGTGTC‑3'; j‑F, 5'‑CCATGCTGTCA TACCACA‑3'; and j‑R, 5'‑GAGAGGCCATTTGAGTGCT‑3'.

Statistical analysis. All data are presented as means of three independent experiments ± standard deviation. GraphPad Prism 7 software (GraphPad Software, Inc.) was used for statistical analyses. Student's t‑tests (two‑tailed, unpaired) were used to determine significant differences between si‑CTL versus si‑KDM3A and Mock versus Flag‑KDM3A in Fig. 1. In Fig. 1, data from normoxia (21% O2) or hypoxia (1% O2) groups were compared independently. Differences in KDM3A ChIP signals between normoxia (21% O2) and hypoxia (1% O2) in Fig. 4C was also analysed with Student's t‑test (two‑tailed, unpaired). Data in Figs. 3B, C and 4E were analysed with one‑way ANOVA followed by Tukey's post hoc test to determine significant differences. P<0.05 was considered to indicate a statistically significant difference.

Results

KDM3A is involved in breast cancer cell invasion in hypoxia. To examine the role of KDM3A in aggressive cancer cell behavior in the hypoxic microenvironment, the involvement of KDM3A in hypoxia‑induced cancer cell phenotypes was determined in the present study. Given the prominent clinical association between hypoxia‑induced response and prognosis of patients with breast cancer (12), the function of KDM3A in MCF7 breast cancer cells was examined. First, the requirement of KDM3A for cell proliferation in hypoxia conditions was observed. It was notable that MCF7 cells incubated in 1% O2 for longer than 24 h showed a higher death rate. Thus, cellular proliferation was determined in milder hypoxic conditions, 5% O2, rather than 1% O2. Under hypoxic conditions (5% O2), MCF7 cells proliferated at a ~5-fold decreased rate compared with that of MCF7 cells cultured in normoxic conditions (21% O2; Fig. 1A). KDM3A deletion did not further aggravate MCF7 cell proliferation in hypoxic conditions. Notably, KDM3A knockdown minimally affected MCF7 cell proliferation in normoxic conditions. In addition, the loss of KDM3A did not trigger cell death in normoxic or hypoxic conditions (1% O2), which was determined by the fluorescent signals generated from cleaved substrate by active caspases in apoptotic cells (Fig. 1B). These results indicate that KDM3A is dispensable for MCF7 cell survival and proliferation under hypoxic stress conditions.
Next, the present study investigated whether KDM3A is associated with hypoxia-induced cell motility, another hypoxia-responsive cell phenotype that promotes the spread of aggressive cancer cells. MCF7 cells poorly invaded through Matrigel-coated Transwell chambers in normoxic conditions, whereas preincubation in hypoxia (1% O\(_2\)) for 24 h induced cell invasion (Fig. 1C and D). Notably, KDM3A depletion decreased hypoxia-induced invasion of MCF7 cells by >2-fold compared with that of si-CTL cells. This finding implies that KDM3A is involved in hypoxia-induced invasive cell motility. To assess whether the upregulation of KDM3A expression in hypoxia is sufficient to induce cancer cell invasion, and whether other hypoxia-induced signalling pathways are necessary, the effect of KDM3A overexpression on MCF7 cell invasion in normoxic conditions was examined (Fig. 1E and F). The invasive capacity of cells transfected with ectopic Flag-KDM3A increased by ~15-fold compared with that of Mock-transfected cells, even in normoxia. This finding supports the notion that the enhanced expression
of endogenous KDM3A in hypoxic conditions is sufficient to promote hypoxia-induced breast cancer cell invasion. It is notable that ectopic expression of KDM3A had no effect on MCF7 cell invasion in hypoxia. It can be speculated that the robust increase in endogenous KDM3A expression in hypoxia (Fig. 2) may be sufficient to induce cell invasion to the level that is not further enhanced by additional exogenous KDM3A.

**KDM3A promotes hypoxia-induced Slug expression.** Transcriptional alteration is critical for cancer cells to switch phenotypic states in response to microenvironmental conditions. It was hypothesised that KDM3A-mediated chromatin modification is involved in regulating the transcriptional expression of key players promoting cancer cell invasion. E-cadherin, which is encoded by CDH1, is a well-known epithelial cell marker. CDH1 downregulation is a characteristic of EMT, which induces cell motility (13). Under hypoxic conditions (1% O₂ for 24 h), CDH1 mRNA expression in MCF7 cells was largely decreased compared with that in cells cultured under normoxic conditions (Fig. 2A). Compromised CDH1 expression in hypoxic conditions was also observed at the protein level (Fig. 2B). By contrast, KDM3A depletion restored CDH1 expression under hypoxic conditions to levels comparable to those observed in control cells under normoxic conditions (Fig. 2A and B). This finding implies that KDM3A is necessary for hypoxia-induced downregulation of E-cadherin, which is associated with the induction of cell invasion.
Given that KDM3A removes H3K9 methylation, which represses transcription, KDM3A is expected to function as a transcriptional activator. However, enhanced CDH1 expression in KDM3A-depleted hypoxic cells suggests that KDM3A negatively regulates CDH1 expression. To explain this discordant observation, it was hypothesised that decreased CDH1 expression in hypoxia may be a consequence of KDM3A-mediated activation of transcription factor involved in CDH1 expression. Multiple transcription factors are involved in EMT-associated changes in CDH1 expression (14). Among them, Slug, which directly represses CDH1 expression, is induced in hypoxia (15). The present study assessed whether Slug expression was affected by the loss of KDM3A. Consistent with a previous report (15), hypoxic stress (1% O₂ for 24 h) increased Slug expression in MCF7 cells compared with that of control cells. By contrast, KDM3A knockdown led to a prominent decrease in Slug expression levels under hypoxic conditions at both the mRNA and protein levels (Fig. 2A and B). This result suggests that KDM3A upregulates the transcriptional expression of Slug. Consistent with this finding, ectopic overexpression of KDM3A in MCF7 cells increased the expression of Slug, even under normoxic conditions (Fig. 2C and D). In addition, the expression of CDH1 (E-cadherin) at both the mRNA and protein levels was largely decreased by KDM3A overexpression (Fig. 2C and D). Together, these results support that enhanced KDM3A expression upregulates the transcription of Slug, subsequently downregulating CDH1 expression, which is associated with EMT-associated cell invasion. Furthermore, KDM3A depletion decreased the hypoxia-induced expression of Twist, another EMT-associated transcription factor that represses E-cadherin expression (Fig. 2E). Consistently, the ectopic overexpression of KDM3A increased Twist expression under normoxic conditions (Fig. 2F). By contrast, KDM3A knockdown increased hypoxia-induced Snail expression (Fig. 2E). In normoxic cells transfected with KDM3A-overexpressing constructs, Snail protein expression was not detected (Fig. 2E and F). It is likely that an increase in KDM3A alone is not sufficient to induce Snail expression in normoxia but requires additional factor(s) activated in hypoxia. It was not determined as to whether KDM3A-knockdown affected Snail expression in normoxia, as Snail expression appeared not to be associated with KDM3A-dependent E-cadherin repression. To summarise, these results imply that KDM3A mediates the upregulation of Twist in addition to Slug, both of which are involved in the repression of E-cadherin expression.

KDM3A positively regulates the transcriptional activity of the SNAI2 promoter. To understand the molecular mechanism by which KDM3A upregulates the transcription of Slug, the effect of KDM3A depletion on the promoter of the SNAI2 gene, which encodes Slug, was examined. First, a reporter system carrying an ~1-kb fragment encompassing 790 bp upstream to 210 bp downstream of the SNAI2 TSS (+1) fused to the luciferase coding region (Rep-A) was constructed (Fig. 3A). To further define the promoter of SNAI2, an additional reporter system lacking the DNA region spanning -790 bp to -511 bp from the SNAI2 TSS (Rep-B) was generated. A reporter containing only the luciferase gene without a promoter element was used as a negative control (Rep-C). MCF7 cells transfected with each reporter construct were subjected to luciferase assays to assess SNAI2 promoter activity. Cells transfected with both the Rep-A and Rep-B reporters expressed prominent levels of luciferase under hypoxic conditions (1% O₂), as detected by luminescence (Fig. 3B). This
finding indicates that the cloned DNA fragments 5’ upstream of the SNAI2 TSS function as competent promoter elements under hypoxic conditions. Next, KDM3A-specific siRNA along with reporter constructs were simultaneously introduced into MCF7 cells, and reporter activity was measured under the same hypoxic conditions using a quantitative luminescence assay (Fig. 3C). Compared with their activities in si-CTL-transfected cells, cells transfected with si-KDM3A exhibited a statistically significant decrease in the reporter activities of both Rep-A and Rep-B. This finding demonstrates that KDM3A depletion leads to a defect in the transcriptional activity of the SNAI2 promoter under hypoxic conditions.

Dimethylation of histone H3 at lysine 9 (H3K9me2) at the SNAI2 promoter is regulated by the recruitment of KDM3A. Next, to determine whether KDM3A functions as a histone demethylase to alter the chromatin structure of the SNAI2 promoter, whether histone methylation at the SNAI2 promoter region was altered by the loss of KDM3A was examined. In total, 10 primer pairs specific to regions within the SNAI2 promoter and the downstream adjacent DNA element (from -1,500 to +1,000) separated by a ~200-bp interval were designed (Fig. 4A). First, to determine the recruitment of KDM3A to the SNAI2 promoter region, MCF7 cells cultured under normoxic or hypoxic conditions (1% O2) for 24 h were subjected ChIP using an anti-KDM3A-specific antibody, followed by PCR-mediated amplification of the antibody-associated DNA regions. As a non-specific enrichment control, anti-IgG was used as a control antibody. The KDM3A-specific ChIP signals were semi-quantitatively measured by normalization to the IgG ChIP signals. The enrichment of KDM3A was observed in three regions, namely regions d, B and g, which are located approximately -1,100, -350 and -110 bp away from the TSS (+1), respectively. In region d, KDM3A accumulation was detected under both normoxic and hypoxic conditions (Fig. 4B and C). By contrast, KDM3A enrichment at regions B and g was specific to hypoxia. All other regions (A, e, f, h, j, C and j) exhibited minimal KDM3A ChIP signal; implying that, while KDM3A associates with the SNAI2 promoter region ~1,000 bp upstream of the TSS regardless of the oxygen concentration, additional KDM3A is recruited specifically to the SNAI2 promoter region spanning ~350 bp to 110 bp upstream of the TSS (encompassing region B and g) under hypoxic conditions.

Next, chromatin modification at the SNAI2 promoter in MCF7 cells was assessed by ChIP against H3K9me2. In hypoxia, H3K9me2 levels at region B, where hypoxia-induced KDM3A accumulation was detected (Fig. 4B and C), were largely decreased compared with the levels in the other KDM3A-accumulated regions (region A and C; Fig. 4D and E). By contrast, when KDM3A was depleted with siRNA, H3K9me2 levels at region B were not decreased in hypoxic conditions compared with that in normoxic conditions. Therefore, H3K9me2 at region B of the SNAI2 promoter is likely to be demethylated by KDM3A, which is specifically recruited under hypoxic conditions (Fig. 4B and C). Thus, this result suggests H3K9me2-mediated transcriptional repression of SNAI2 is relieved under low-oxygen conditions. KDM3A depletion mediated a decrease in H3K9me2 at region B under normoxic conditions (Fig. 4D and E). It is possible that the functional involvement of KDM3A in demethylating the SNAI2 promoter may be distinctive between normoxic and hypoxic conditions, which was not further characterized in the present study.

Discussion

The phenotypic change of cancer cells in the hypoxic tumour microenvironment promotes aggressive cancer progression (1). Understanding the molecular mechanisms underlying hypoxia-mediated cancer cell state transition will pave the way to develop treatment strategies. Epigenetic modifications to mediate transcriptional alteration are crucial for cellular state transitions (16). Accordingly, attempts have been made to characterize the functional implication of epigenetic modifications, including lysine demethylase-mediated chromatin alterations in hypoxia-mediated transcriptional modulation (17). In this context, the present study demonstrated the functional involvement of KDM3A in the hypoxia-induced metastatic potential of breast cancer cells through increased invasion. Mechanistically, KDM3A, the expression of which is increased by HIF-1 under hypoxic conditions, is recruited to remove the transcriptionally repressive histone modification marker H3K9me2 from the promoter of SNAI2, which encodes Slug, an EMT transcription factor. Consequently, the increased expression of Slug decreases the expression of CDH1-encoded E-cadherin, which is a distinctive characteristic of EMT that confers cancer cell metastatic potential. These results collectively suggest that KDM3A is a transcriptional coactivator of Slug expression that induces cancer cell invasion in hypoxia. In addition, KDM3A is involved in the induction of Twist expression in hypoxia, which also promotes invasive cancer cell motility. Of note, the changes in Slug or Twist expression in the cells with or without KDM3A knockdown were modest compared with those in E-cadherin expression. It is likely that the dysregulation of E-cadherin expression in cells with KDM3A depletion is cooperatively mediated by a simultaneous decrease in Slug and Twist expression following KDM3A knockdown. Future studies may reveal whether KDM3A would be also recruited to the Twist promoter in hypoxia to regulate its chromatin structure.

Consistent with the results of the present study, the transcriptional coactivator activity of KDM3A has previously been observed in rat trophoblast stem cell differentiation under hypoxic conditions by Chakraborty et al (18). By systemic analyses of the upregulated genes in rats exposed to low oxygen, the study found that matrix metalloproteinase 12 (MMP12) is a crucial gene associated with hypoxia-induced cell invasion. In addition, the study showed that, in hypoxia, KDM3A-mediated H3K9 demethylation is required for the expression of MMP12, which is not a direct target of HIF-1 (18). This finding implies that KDM3A, the expression of which is upregulated by HIF-1, functions as a transcriptional coactivator to facilitate the expression of genes involved in hypoxia-induced cellular state transitions such as MMP12. Additionally, in urinary bladder cancer, KDM3A cooperates with HIF-1 to enhance glycolysis and thereby promote cancer cell proliferation (19). By demonstrating that the catalytically inactive KDM3A mutant failed to act as a transcriptional coactivator of HIF-1, the bladder cancer study suggests the importance of KDM3A-mediated
chromatin modification in the transcriptional regulation associated with aggressive cancer progression in the hypoxic tumour microenvironment. The KDM3A-mediated decrease in H3K9me2 at the SNAI2 promoter in hypoxic breast cancer cells observed in the present study also strongly supports the involvement of KDM3A-dependent chromatin modifications in hypoxic cancer progression.

The involvement of KDM3A in aggressive cancer cell phenotypes was also reported in an aggressive form of breast cancer in a previous study (20). In contrast to the results of the present study demonstrating the necessity of KDM3A in the induction of cellular invasion under hypoxic conditions, the aforementioned study showed that, in the metastatic breast cancer cell lines MDA-MB-231 and Hs578T, KDM3A...
knockdown inhibited cell invasion under normoxic conditions by demethylating H3K9 at pro-invasive genes such as MMP9 and S100A4. This result, along with our finding that KDM3A is required for the hypoxic induction of breast cancer cell invasion likely through promoting the expression of Slug, an EMT-associated transcription factor, suggests that KDM3A not only establishes but also maintains the metastatic potential of breast cancer cells. Notably, while Wade et al. (21) reported the requirement of KDM3A for estrogen receptor signalling-dependent proliferation of MCF7 breast cancer cells in oestriadiol-supplemented medium, the present study failed to observe the detrimental effect of KDM3A on MCF7 cell survival or proliferation in high-glucose DMEM (Fig. 1A and B). It can be speculated that the requirement of KDM3A for MCF7 breast cancer cell survival and proliferation may be largely dependent on growth conditions. The mechanism by which KDM3A is recruited to distinct target genes in different oxygen concentrations such as MDA-MB-231 in normoxia vs. MCF7 in hypoxia, remains unknown. Future studies to identify KDM3A-interacting transcription factors that promote cancer cell invasion will reveal detailed information about hypoxia-induced transcriptional alterations associated with the transition of cancer cells to a more aggressive state.

Acknowledgements

The authors would like to thank Dr Hyun-Soo Cho (Korea Research Institute of Bioscience and Biotechnology, Daejeon, Republic of Korea) for providing the Flag-KDM3A construct.

Funding

The present study was supported by the National Research Foundation of Korea funded by the Ministry of Science and Information & Communication Technology (grant nos. NRF-2013R1A1A1066638 and NRF-2019R1A2C1086151) and by the KIRIBB Research Initiative Program.

Authors’ contributions

HJA and JAK conceived and designed the study. HJA, BM, and MP performed the experiments and analyzed the data. JAK wrote the manuscript. All authors read and approved the final manuscript and agreed to be accountable for all aspects of the research.

Availability of data and materials

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Ethics approval and consent to participate

Not applicable.

Patient consent for publication

Not applicable.

Competing interests

The authors declare that they have no competing interests.

References

1. Rankin EB, Nam JM and Giaccia AJ: Hypoxia: Signaling the Metastatic Cascade. Trends Cancer 2: 295-304, 2016.
2. Eales KL, Hollinshead KE and Tennant DA: Hypoxia and metabolic adaptation of cancer cells. Oncogene 5: e190, 2016.
3. Chouaib S, Messai Y, Couve S, Escudier B, Hasmim M and Noman MZ: Hypoxia promotes tumor growth in linking angiogenesis to immune escape. Front Immunol 3: 21, 2012.
4. Semenza GL: Hypoxia-inducible factors in physiology and medicine. Cell 148: 399-408, 2012.
5. Xia X, Lemieux ME, Li W, Carroll JS, Brown M, Liu XS and Kung AL: Integrative analysis of HIF binding and transactivation reveals its role in maintaining histone methylation homeostasis. Proc Natl Acad Sci USA 106: 4260-4265, 2009.
6. Hancock RL, Dunne K, Walport LJ, Flashman E and Kawamura A: Epigenetic regulation by histone demethylases in hypoxia. Epigenomics 7: 791-811, 2015.
7. Luo W, Chang K, Zhong J, Pandey A and Semenza GL: Histone demethylase JMJD2C is a coactivator for hypoxia-inducible factor 1 that is required for breast cancer progression. Proc Natl Acad Sci USA 109: E3367-E3376, 2012.
8. Mirnira I, Nangaku M, Kannki Y, Tsutsuini S, Inoue T, Kohroo S, Yamamoto S, Fujita T, Shimamura T, Suehiro J, et al: Dynamic change of chromatin conformation in response to hypoxia enhances the expression of GLUT3 (SLC2A3) by cooperative interaction of hypoxia-inducible factor 1 and KDM3A. Mol Cell Biol 32: 3018-3032, 2012.
9. Lee HY, Yang EG and Park H: Hypoxia enhances the expression of prostate-specific antigen by modulating the quantity and catalytic activity of Junmonji C domain-containing histone demethylases. Carcinogenesis 34: 2706-2715, 2013.
10. Park SJ, Kim JG, Son TG, Yi JM, Kim ND, Yang K and Heo K: The hypoxia demethylase JMJD1A regulates adenomedullin-mediated cell proliferation in hepatocellular carcinoma under hypoxia. Biochem Biophys Res Commun 434: 722-727, 2013.
11. Udai J, Ho JC, Lee KL, Kitajima S, Yang H, Sun W, Fukuhara N, Zaiden N, Chan SL, Tachibana M, et al: The hypoxia-inducible epigenetic regulators Mjmd1a and G9a provide a mechanistic link between angiogenesis and tumor growth. Mol Cell Biol 34: 3702-3720, 2014.
12. Favaro E, Lord S, Harris AL and Bufta FM: Gene expression and hypoxia in breast cancer. Genome Med 3: 55, 2011.
13. Lamouille S, Xu J and Derynick R: Molecular mechanisms of epithelial-mesenchymal transition. Nat Rev Mol Cell Biol 15: 178-194, 2014.
14. Serrano-Gomez SJ, Maziveyi M and Alahari SK: Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications. Mol Cancer 15: 18, 2016.
15. Jiang J, Tang YL and Liang XH: EMT: A new vision of hypoxia promoting cancer progression. Cancer Biol Ther 11: 714-721, 2011.
16. Flavahan WA, Gaskell E and Bernstein BE: Epigenetic plasticity and the hallmarks of cancer. Science 357: eaal2380, 2017.
17. Perez-Petrei JI, Acevedo JM and Wappper P: Epigenetics: New questions on the response to hypoxia. Int J Mol Sci 12: 4705-4721, 2011.
18. Chakraborty D, Cui W, Rosario GX, Scott RL, Dhakal P, Renaud SJ, Tachibana M, Rumi MA, Mason CW, Krieg AJ, et al: Jumonji C domain-containing histone demethylase JMJD3A-MMP12 regulatory circuit ensures trophoblast plasticity and placental adaptations to hypoxia. Proc Natl Acad Sci USA 113: E7212-E7221, 2016.
19. Wan W, Feng K, Li M, Qin L, Tong Z, Yan J, Shen B and Yu C: Histone demethylase JMJD1A promotes uterine bladder cancer progression by enhancing glycolysis through coactivation of hypoxia inducible factor 1α. Oncogene 36: 3868-3877, 2017.
20. Ramadoss S, Guo G and Wang C-Y: Lysine demethylase KDM3A regulates breast cancer cell invasion and apoptosis by targeting histone and the non-histone protein p53. Oncogene 36: 47-59, 2017.
21. Wade MA, Jones LD, Wilson L, Stockley J, Woffey K, Robson CN and Gaughan L: The histone demethylase enzyme KDM3A is a key estrogen receptor regulator in breast cancer. Nucleic Acids Res 43: 196-207, 2015.

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) License.